"Designing Growth Strategies is in our DNA"
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1 Prevalence of Diabetes - For Key Countries, 2018
4.2 Pipeline Analysis
4.3 Key Industry Developments –Mergers, Acquisitions and Partnerships
4.4 Introduction of New Drugs/Approvals (by major players)
4.5 Overview of Regulatory Scenario of Key Countries/ Regions
5. Global Diabetes Drugs Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Drug Class
5.2.1 Insulin
5.2.2 DPP-4 Inhibitors
5.2.3 GLP-1 Receptor Agonists
5.2.4 SGLT2 Inhibitors
5.2.5 Others
5.3. Market Analysis, Insights and Forecast – By Diabetes Type
5.3.1 Diabetes 1
5.3.2 Diabetes 2
5.4 Market Analysis, Insights and Forecast – By Route of Administration
5.4.1 Oral
5.4.2 Subcutaneous
5.4.3 Intravenous
5.5. Market Analysis, Insights and Forecast – By Distribution Channel
5.5.1 Online pharmacies
5.5.2 Hospital Pharmacies
5.5.3 Retail Pharmacies
5.6. Market Analysis, Insights and Forecast – By Region
5.6.1 North America
5.6.2 Europe
5.6.3 Asia Pacific
5.6.4 Latin America
5.6.5 Middle East & Africa
6. North America Diabetes Drugs Market Analysis, Insights and Forecast, 2015-2026
6.1. Key Findings / Summary
6.2. Market Analysis, Insights and Forecast – By Drug Class
6.2.1 Insulin
6.2.2 DPP-4 Inhibitors
6.2.3 GLP-1 Receptor Agonists
6.2.4 SGLT-2 Inhibitors
6.2.5 Others
6.3. Market Analysis, Insights and Forecast – By Diabetes Type
6.3.1 Diabetes 1
6.3.2 Diabetes 2
6.4. Market Analysis, Insights and Forecast – By Route of Administration
6.4.1 Oral
6.4.2 Subcutaneous
6.4.3 Intravenous
6.5. Market Analysis, Insights and Forecast – By Distribution Channel
6.5.1 Online pharmacies
6.5.2 Hospital Pharmacies
6.5.3 Retail Pharmacies
6.6. Market Analysis, Insights and Forecast – By Country
6.6.1 U.S.
6.6.2 Canada
7. Europe Diabetes Drugs Market Analysis, Insights and Forecast, 2015-2026
7.1. Key Findings / Summary
7.2. Market Analysis, Insights and Forecast – By Drug Class
7.2.1 Insulin
7.2.2 DPP-4 Inhibitors
7.2.3 GLP-1 Receptor Agonists
7.2.4 SGLT-2 Inhibitors
7.2.5 Others
7.3. Market Analysis, Insights and Forecast – By Diabetes Type
7.3.1 Diabetes 1
7.3.2 Diabetes 2
7.4. Market Analysis, Insights and Forecast – By Route of Administration
7.4.1 Oral
7.4.2 Subcutaneous
7.4.3 Intravenous
7.5. Market Analysis, Insights and Forecast – By Distribution Channel
7.5.1 Online pharmacies
7.5.2 Hospital Pharmacies
7.5.3 Retail Pharmacies
7.6. Market Analysis, Insights and Forecast – By Country/ Sub-region
7.6.1 UK
7.6.2 Germany
7.6.3 France
7.6.4 Italy
7.6.5 Spain
7.6.6 Scandinavia
7.6.7 Rest of Europe
8. Asia Pacific Diabetes Drugs Market Analysis, Insights and Forecast, 2015-2026
8.1. Key Findings / Summary
8.2. Market Analysis, Insights and Forecast – By Drug Class
8.2.1 Insulin
8.2.2 DPP-4 Inhibitors
8.2.3 GLP-1 Receptor Agonists
8.2.4 SGLT-2 Inhibitors
8.2.5 Others
8.3. Market Analysis, Insights and Forecast – By Diabetes Type
8.3.1 Diabetes 1
8.3.2 Diabetes 2
8.4. Market Analysis, Insights,and Forecast – By Route of Administration
8.4.1 Oral
8.4.2 Subcutaneous
8.4.3 Intravenous
8.5. Market Analysis, Insights and Forecast – By Distribution Channel
8.5.1 Online pharmacies
8.5.2 Hospital Pharmacies
8.5.3 Retail Pharmacies
8.6. Market Analysis, Insights and Forecast – By Country/ Sub-region
8.6.1 China
8.6.2 India
8.6.3 Japan
8.6.4 Australia
8.6.5 South East Asia
8.6.6 Rest of Asia Pacific
9. Latin America Diabetes Drugs Market Analysis, Insights and Forecast, 2015-2026
9.1. Key Findings / Summary
9.2. Market Analysis, Insights and Forecast – By Drug Class
9.2.1 Insulin
9.2.2 DPP-4 Inhibitors
9.2.3 GLP-1 Receptor Agonists
9.2.4 SGLT-2 Inhibitors
9.2.5 Others
9.3. Market Analysis, Insights and Forecast – By Diabetes Type
9.3.1 Diabetes 1
9.3.2 Diabetes 2
9.4. Market Analysis, Insights and Forecast – By Route of Administration
9.4.1 Oral
9.4.2 Subcutaneous
9.4.3 Intravenous
9.5. Market Analysis, Insights and Forecast – By Distribution Channel
9.5.1 Online pharmacies
9.5.2 Hospital Pharmacies
9.5.3 Retail Pharmacies
9.6. Market Analysis, Insights and Forecast – By Country/ Sub-region
9.6.1 Brazil
9.6.2 Mexico
9.6.3 Rest of Latin America
10. Middle East &Africa Diabetes Drugs Market Analysis, Insights and Forecast, 2015-2026
10.1. Key Findings / Summary
10.2. Market Analysis, Insights and Forecast – By Drug Class
10.2.1 Insulin
10.2.2 DPP-4 Inhibitors
10.2.3 GLP-1 Receptor Agonists
10.2.4 SGLT-2 Inhibitors
10.2.5 Others
10.3. Market Analysis, Insights,and Forecast – By Diabetes Type
10.3.1 Diabetes 1
10.3.2 Diabetes 2
10.4. Market Analysis, Insights,and Forecast – By Route of Administration
10.4.1 Oral
10.4.2 Subcutaneous
10.4.3 Intravenous
10.5. Market Analysis, Insights,and Forecast – By Distribution Channel
10.5.1 Online pharmacies
10.5.2 Hospital Pharmacies
10.5.3 Retail Pharmacies
10.6. Market Analysis, Insights,and Forecast – By Country/ Sub-region
10.6.1 GCC
10.6.2 South Africa
10.6.3 Rest of Middle East and Africa
11. Competitive Analysis
11.1. Key Industry Developments
11.2. Global Market Share Analysis (2018)
11.3. Company Profiles (Overview,Products & services, SWOT analysis, Recent developments, strategies,financials (based on availability))
11.3.1 Novo Nordisk India Pvt Ltd
11.3.2 Sanofi
11.3.3 Merck& Co., Inc.
11.3.4 Eli Lilly and Company.
11.3.5 Astra Zeneca
11.3.6 Takeda Pharmaceutical Company Limited
11.3.7 Boehringer Ingelheim International GmbH
11.3.8 Novartis AG
11.3.9 Johnson & Johnson Services, Inc.
11.3.10 Bayer AG
11.3.11 Other Players
Related Reports